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To the Editor: Relapsing fevers are paroxysmal 
bloodstream infections caused by spirochetes of the genus 
Borrelia. Louseborne relapsing fever (LBRF; i.e., epidemic 
relapsing fever) is caused by B. recurrentis and transmit-
ted by the human body louse (Pediculus humanus). Soft 
ticks of the Argasidae family (e.g., Ornithodorus moubata) 
are vectors for tickborne relapsing fever (TBRF) borreliae, 
which encompass several human-pathogenic species. In 
Europe, LBRF was epidemic in the early 20th century but 
is now rarely seen. We report an infection with B. recur-
rentis imported to Germany by a Somalian refugee who 
had high fever and hemoptysis and describe the process of 
molecular diagnosis.
In August 2015, an 18-year-old man sought asylum in 
Germany after travel through Somalia, Ethiopia, Sudan, Lib-
ya, and Italy. He reported general weakness and fever while 
in Libya, ≈16 days before seeking care, and started cough-
ing up blood after arriving in Italy. At hospital admission in 
Germany, he had a temperature up to 40.4°C, cough, and he-
moptysis; his suspected diagnosis was tuberculosis. No ec-
toparasites were reported or found on physical examination. 
Abnormal laboratory findings included relative neutrophilia 
(91% [reference 39%–77%]), thrombocytopenia (platelets 
112 × 10³/mL [reference 160–385 × 10³/mL]), and prolonged 
activated partial thromboplastin time (APTT) (Figure, panel 
A). Because of highly elevated levels of C-reactive protein 
(250 mg/L [reference <5 mg/L]) and procalcitonin (16.4 
µg/L [reference <0.5 µg/L]), the patient was treated with 
ceftriaxone (2g/d intravenously), metronidazole (500 mg/d 
intravenously), and paracetamol (acetaminophen). Repeated 
examinations of Giemsa-stained thick and thin blood slides 
were negative for malaria parasites. Blood cultures, tests for 
tuberculosis, and PCRs for Rift Valley fever, yellow fever, 
dengue, and chikungunya viruses also were negative. With 
antimicrobial therapy, the patient’s fever declined within 12 
hours, but platelet counts further decreased and APTT con-
tinued to increase (Figure, panel A).
The patient’s symptoms and travel history raised sus-
picion of a spirochete infection. A plasma sample from his 
second day in the hospital tested positive for Borrelia spp. 
16S DNA by real-time PCR (1). Retrospective microscopy 
revealed a low number of extracellular spirochetes in thin 
blood smears (Figure, panel B). The antimicrobial regimen 
was changed to doxycycline (100 mg 2×/d) on day 7 after 
admission and, because species identification had not been 
completed, continued for 10 days. No signs of a Jarisch-
Herxheimer reaction were seen. During days 4–9 after ad-
mission, APTT, platelet counts (Figure, panel A), and C-
reactive protein values returned to normal, and the patient 
was discharged.
For species identification, we amplified the entire cod-
ing sequence of glpQ (glycerophosphodiester phosphodi-
esterase) with newly designed primers (online Technical 
Appendix, http://wwwnc.cdc.gov/EID/article/22/5/15-1557-
Techapp1.pdf). The amplicon was 100% (1,002/1,002 bp) 
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identical to B. recurrentis A1 (GenBank accession no. 
CP000993.1) and 99% identical (999/1,002 bp) to B. dutto-
nii Ly (GenBank accession no. CP000976.1). A phylogenetic 
analysis that included 7 published glpQ sequences from B. 
recurrentis and 4 from B. duttonii suggested that the detected 
pathogen clustered with B. recurrentis and not B. duttonii 
(Figure, panel C).
Borreliae have been recognized as a frequent cause 
of febrile infections in West and East Africa (2). Data on 
the incidence in immigrants are not available, but the re-
cent increase in asylum seekers from East Africa arriving 
in Central Europe has increased attention of Borrelia as a 
pathogen to be included in differential diagnoses of febrile 
infections (3,4). Because symptom onset in the patient we 
report occurred in Libya, he most likely acquired infection 
on the African continent, although local transmission in 
Europe can occur (4).
Blood slide examination, which would show spiro-
chetes, is routinely requested to detect Plasmodium para-
sites, but its sensitivity in detecting borreliae is strikingly 
inferior to molecular tools (15%–56%, depending on 
laboratory conditions) (1). Pan-Borrelia real-time PCRs 
enable sensitive detection of DNA in blood samples, fol-
lowed by sequencing (1) or confirmatory PCRs for re-
lapsing fever Borrelia–specific genes (e.g., glpQ) (5,6). 
B. recurrentis is genetically highly similar to B. duttonii, 
suggesting it might be a degraded subset of its tickborne 
counterpart rather than a distinct species (7). Yet, phy-
logeny of whole glpQ sequences enables separation of B. 
recurrentis from B. duttonii on the basis of distinct sin-
gle-nucleotide variations. Alternatively, differentiation 
can be achieved by phylogenetic analysis of concatenated 
partial 16s, glpQ and flaB (flagellin) sequences (5). Dif-
ferentiation between TBRF and LBRF is crucial for the 
correct clinical decision on therapy duration, independent 
of the antimicrobial substance chosen: at least 7 days of 
treatment is recommended for TBRF to prevent relapses 
after early invasion of spirochetes into the central ner-
vous system (8), whereas a single-dose regimen is suf-
ficient for LBRF (9), although longer treatment courses 
tend to be used.
In summary, our report emphasizes that LBRF can be 
complicated by pulmonary hemorrhages associated with 
impaired platelet and plasmatic coagulation (10), which 
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Figure. Laboratory findings of hemorrhagic diathesis in an 18-year-old Somalian refugee to Germany with Borrelia recurrentis infection, 
August 2015. A) Time course of coagulation parameters (thrombocytopenia and prolongation of activated partial thromboplastin time 
[APTT]). B) Extracellular spirochetes demonstrated by light microscopy (arrowhead). Representative image detail from thin blood 
smear, Giemsa stain. Scale bar indicates .5 mm. C) Molecular phylogenetic analysis of B. recurrentis detected in patient blood. Multiple 
alignment of complete glpQ sequence (1,002 bp) with published reference sequences was performed by using BioEdit 7.0.5.3 software 
(Ibis Biosciences, Carlsbad, CA, USA) and analyzed by MEGA6.06 (http://www.megasoftware.net). The evolutionary history was 
inferred by using maximum-likelihood method based on the Tamura-Nei model. Bootstrap values are shown at the node of branches 
(1,000 bootstrap replications). The complete glpQ sequence was deposited in GenBank under accession no. KT764112. Scale bar 
indicates nucleotide substitutions per site.
can be mistaken for signs of tuberculosis. Considering the 
poor hygienic conditions among refugees, LBRF has be-
come an important differential diagnosis in Europe in times 
of increasing migration.
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To The Editor: Crimean-Congo hemorrhagic fever 
(CCHF) is a highly infectious tickborne disease caused 
by a high-risk group of viruses belonging to the family 
Bunyaviridae (1,2). In humans, the overall case-fatality 
rate of CCHF is ≈30%, but in severe and hospitalized 
patients, fatalities may be up to 80% (3,4). CCHF is 
widespread in various countries in Africa, Asia, and Eu-
rope; the virus had been identified in humans in China, 
Pakistan, and Afghanistan and has been recently report-
ed for the first time in humans in India (4–7). Humans 
can be infected by bites from infected ticks, mainly of 
the Hyalomma genus; by unprotected contact with blood 
or tissue of viremic patients; or during slaughtering of 
infected animals. In addition, nosocomial infections are 
found in humans (1,4,8,9).
Fatal cases of CCHF in humans were confirmed in 
Ahmadabad in India in 2011, but a recent serosurvey in 
livestock showed that this disease has widespread serop-
revalence in domestic animals across India (7–10). Bhutan 
shares a long, porous border with India, and animals and 
humans frequently cross the border. Comprehensive sur-
veillance was needed to determine the presence of CCHF 
virus (CCHFV) in livestock in Bhutan and to assess risk for 
zoonotic infection in humans.
During October 2015, in collaboration with the Na-
tional Centre for Animal Health Bhutan, we retrospective-
ly tested serum samples collected during April–May 2015 
from 81 goats and 92 cattle for CCHFV-specific IgG by 
using ELISA kits (Sheep/goat anti-CCHFV IgG ELISA kit 
and Cattle anti-CCHFV IgG ELISA kit; National Institute 
of Virology, Pune, India), as described (10). CCHFV IgG 
was detected in 31 (38.2%) goats; no cattle had positive 
results. The samples from goats, which were collected in 
early 2015 as part of surveillance of peste des petits ru-
minants, originated from the southern district of Sarpang, 
which shares a porous border with the state of Assam in 
India (Figure). The samples from cattle were collected 
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